Adrian Rawcliffe - Feb 20, 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
Chief Executive Officer, Director
Signature
/s/ Adrian George Rawcliffe
Stock symbol
ADAP
Transactions as of
Feb 20, 2025
Transactions value $
$0
Form type
4
Date filed
2/20/2025, 05:30 PM
Previous filing
Jan 17, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADAP Option to purchase Ordinary Shares Award $0 +5.14M $0.00 5.14M Feb 20, 2025 Ordinary Shares 5.14M $0.10 Direct F1, F2
transaction ADAP Option to purchase Ordinary Shares Award $0 +3.43M $0.00 3.43M Feb 20, 2025 Ordinary Shares 3.43M $0.00 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2 Exercisable as to 1,285,812 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 107,148 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 107,256 Ordinary Shares on February 20, 2029.
F3 The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4 Exercisable as to 857,208 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 857,208 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.
F5 The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.